The DOI matches its Crossref record.
Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate
Abstract
Leukemic blast cells express the CD33 antigen in most patients with acute myeloid leukemia (AML), but this antigen is not expressed by hematopoietic stem cells. We conducted a study to determine whether normal hematopoiesis could be restored in patients with AML by selective ablation of cells expressing the CD33 antigen. In a dose escalation study, 40 patients with relapsed or refractory CD33+ AML were treated with an immunoconjugate (CMA-676) consisting of humanized anti-CD33 antibody linked to the potent antitumor antibiotic calicheamicin. The capacity of leukemic cells to efflux 3,3’-diethyloxacarbocyanine iodide (DiOC2) was used to estimate pretreatment functional drug resistance. Leukemia was eliminated from the blood and marrow of 8 (20%) of the 40 patients; blood counts returned to normal in three (8%) patients. A high rate of clinical response was observed in leukemias characterized by low dye efflux in vitro. Infusions of CMA-676 were generally well tolerated, and a postinfusion syndrome of fever and chills was the most common toxic effect. Two patients who were treated at the highest dose level (9 mg/m2) were neutropenic >5 weeks after the last dose of CMA-676. These results show that an immunoconjugate targeted to CD33 can selectively ablate malignant hematopoiesis in some patients with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 20
- Andrews, 1983, Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies., Blood, 62, 124, 10.1182/blood.V62.1.124.124 · DOI · Paper page
- Griffin, 1984, A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells., Leuk Res, 8, 521, 10.1016/0145-2126(84)90001-8 · DOI · Paper page
- Dinndorf, 1986, Expression of normal myeloid-associated antigens by acute leukemia cells., Blood, 67, 1048, 10.1182/blood.V67.4.1048.1048 · DOI · Paper page
- Andrews, 1989, Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties., J Exp Med, 169, 1721, 10.1084/jem.169.5.1721 · DOI · Paper page
- Bernstein, 1987, Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed., J Clin Invest, 79, 1153, 10.1172/JCI112932 · doi:10.1172/jci112932
- Bernstein, 1992, Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia., Blood, 79, 1811, 10.1182/blood.V79.7.1811.1811 · doi:10.1182/blood.v79.7.1811.1811
- Scheinberg, 1991, A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide., J Clin Oncol, 9, 478, 10.1200/JCO.1991.9.3.478 · DOI · Paper page
- Appelbaum, 1992, The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia., Transplantation, 54, 829, 10.1097/00007890-199211000-00012 · doi:10.1097/00007890-199211000-00012
- van der Jagt, 1992, Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model., Cancer Res, 52, 89
- Zein, 1988, Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically., Science, 240, 1198, 10.1126/science.3240341 · DOI · Paper page
- Leith, 1995, Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux-cases., Blood, 86, 2329, 10.1182/blood.V86.6.2329.bloodjournal8662329 · DOI · Paper page
- Fialkow, 1987, Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia., N Engl J Med, 317, 468, 10.1056/NEJM198708203170802 · DOI · Paper page
- Mehrotra, 1995, Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia., Blood, 86, 1139
- Haase, 1995, Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations., Blood, 86, 2906, 10.1182/blood.V86.8.2906.2906 · DOI · Paper page
- Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell., Nature Med, 3, 730, 10.1038/nm0797-730 · DOI · Paper page
- Niederwieser, 1990, Inadvertent transmission of a donor’s acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia., N Engl J Med, 322, 1794, 10.1056/NEJM199006213222507 · doi:10.1056/nejm199006213222507
- Sievers, 1998, Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse., Blood, 92, 613a
- Jurcic, 1997, Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL)., Blood, 90, 416a
- Caron, 1998, Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia., Clin Cancer Res, 4, 1421
- Robertson, 1992, Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia., Blood, 79, 2229, 10.1182/blood.V79.9.2229.2229 · DOI
Cited by
Gamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3628 · Cited by 486
Self-citationGoldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 438
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000) · Blood · doi:10.1182/blood.v96.2.483.014k40_483_490 · Cited by 202
Zhu, Y., Liu, K., Wang, K., & Zhu, H. (2023) · Cancer · doi:10.1002/cncr.34507 · Cited by 192
Metadata
- Authors
- Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1999-06-01
- Volume
- 93
- Issue
- 11
- Pages
- 3678-3684
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W192515921
- Cited by
- 512
- References
- 0
- FWCI
- 23.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate. https://app.cochat.ai/papers/10.1182/blood.v93.11.3678
- The paper
- Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999). Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate. Blood. https://doi.org/10.1182/blood.v93.11.3678
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
